By admin 
REDWOOD CITY, Kalifornien – Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company with a market capitalization of US$5.3 billion and a 40% end-to-end appreciation in the US dollar, which is an einreichung Zulassungsantrags (New Drug Application, NDA) with the US Food and Drug Administration (FDA) for relacorilant can be used. Relacorilant is a study into the treatment of patients with Cushing’s syndrome, even if endogenous hypercortisolism may occur. Laut Analysis from InvestingPro revealed higher profitability with a gross margin of 98.4%.
The study has shown positive results from the GRACE study, which leads from the phase 3 GRADIENT study, long-term recovery studies and a phase 2 study in hypercortisolism. If the patient is involved in hypercortisolism treatment, there is a symptom, while there is an adverse behavior, while the active treatment is likely to be affected, such as hypokalemia or QT prolongation.
Relacorilant is a selective cortisol modulator, which works with the glucocorticoid receptor and other hormonal receptors. This specific equipment can be a good security profile. Wirkstoff designation in the United States and the European Union is orphan drug designation for the treatment of Cushing’s syndrome.
Cushing’s syndrome is an erection, which is caused by excessive cortisol, and is one of the various healthy problems with blood pressure, central adiposity and many erschöpfung fuhren. Untreatable can be a problem.
The CEO of Corcept, Dr. Joseph Belanoff, likely has the potential to treat patients with hypercortisolism and treat the disease, which could help the drug support its standard of treatment. If the market has optimal optimism, the action in the future will yield a remarkable result of 61.5%. InvestingPro subscribers have 14 years of experience with expert assessments of CORT’s Wachstumspotenzial and Marktposition.
Corcept Therapeutics has a long history of developing Cortisol Modulators and has developed more than 1,000 of its own molecules in 25 years. The portfolio of our external companies is very well managed through sound investments and solid investments. In February 2012, Corcept Korlym® became one of the first FDA-approved treatments for Cushing’s syndrome.
The Mitteilung des Unternehmens offers a so-called targeted forecast of the Wirksamkeit, Sicherheit, potentiation of the Zulassung and kommerziellen of Relacorilant. The strong financial environment of the internal economy was reflected in the active development of 3.7 broader, was robust liquidity through an economic initiative of the Hindu initiative. InvestingPro’s comprehensive Forschungsbericht contains a detailed analysis of the financial stability and financial statements of CORT, which includes 1,400+ other Top US Actions. When you are at the beach, this guarantee is no longer guaranteed to cover your lifestyle, risks and concerns.
These following messages are based on a press conference from Corcept Therapeutics Incorporated.
In others active Entwicklungen verzeichnete Corcept Therapeutics Incorporated more bedeutende Fortschritte. This unit reported a robust quarterly investment of US$182.5 million, representing a 48% increase in full-year profit and a net profit of US$47.2 million. Information estimates are based on an expected growth forecast for 2024 of US$675 to US$700 million.
In clinical research, there is a phase 4 CATALYST study in the first phase of the study and the study that the blutzucker level in patients with hypercortisolism and the control of type 2 diabetes has a significant effect. The Phase 2 DAZALS study with consequences is no longer the primary endpoint in patients with ALS, but the excess of one of the studies on the development of the disease.
I think it is a challenge for a relacorilant, a treatment for Cushing’s syndrome, a study through the positive attitude of the GRACE and GRADIENT study, who of InvestPro noted. Trotz has acquired Teva Pharmaceuticals’ rights to a generic version of Korlym, but we’ll see a $3-billion-dollar takeover years later.
This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.